Cytopia Vows Fight To Keep Avexa From Progen In All-Australia Battle
This article was originally published in PharmAsia News
Executive Summary
Australia's Cytopia is urging shareholders of Avexa to vote for its firm to merge with the biotech in late March to stave off any new hostile takeovers. Cytopia CEO Andrew Macdonald said he is not through yet in his battle to keep Progen Pharmaceuticals from trying to obtain control of Avexa, and urged shareholders to ignore Progen's promise it is ready to begin commercializing Avexa's PI-88 drug and already is in talks with Taiwain regulators. Cytopia said in an interview the Progen assertion was just a smokescreen. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.